中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.027 seconds)

    난소암 환자의 항암제 치료 반응성 예측을 위한 마커 KDM4D
    33.
    发明授权
    난소암 환자의 항암제 치료 반응성 예측을 위한 마커 KDM4D 有权
    KDM4D，用于预防患有癌症患者的抗癌药物的反应标记

    公开(公告)号：KR101540052B1

    公开(公告)日：2015-07-28

    申请号：KR1020140024663

    申请日：2014-02-28

    Applicant: 이화여자대학교 산학협력단

    Inventor： 박윤정 ,  박애경 ,  안정혁 ,  주웅 ,  임진영

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886

    Abstract: 본발명은 KDM4D (Lysine-Specific Demethylase 4D) 의발현수준을검출함으로써, 난소암환자의항암제치료반응성을예측하기위한조성물, 키트및 방법에관한것이다.

    Abstract translation: 本发明涉及通过检测赖氨酸特异性脱甲基酶4D（KDM4D）的表达水平来预测卵巢癌患者的抗癌药物的治疗反应的组合物，试剂盒和方法。 本发明的生物标志物预测患者的反应和抗癌药物对抗癌化疗的抗性风险程度，从而有效地用于选择具有抗癌药物治疗作用的患者或确定抗癌药物的治疗 患者。

    ＮＴＮ4 유전자의 ＣｐＧ 메틸화 변화를 이용한 난소암 전이 진단용 조성물 및 이의 이용
    34.
    发明授权
    ＮＴＮ4 유전자의 ＣｐＧ 메틸화 변화를 이용한 난소암 전이 진단용 조성물 및 이의 이용 有权
    使用NTN4基因的CPG甲基化状态诊断卵巢癌的分子特征的组合物及其用途

    公开(公告)号：KR101384326B1

    公开(公告)日：2014-04-10

    申请号：KR1020130107543

    申请日：2013-09-06

    Applicant: 이화여자대학교 산학협력단

    Inventor： 안정혁 ,  주웅 ,  성혜윤

    IPC: C12Q1/68 ,  G01N33/574 ,  C12N15/11 ,  C12Q1/34

    CPC classification number: C12Q1/6886 ,  C12N15/11 ,  C12Q1/34 ,  C12Q1/683 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  G01N33/57449

    Abstract: The present invention relates to a composition for diagnosing metastatic characteristics or estimating the metastasis riskness of ovarian cancer by detecting the CpG methylation status of NTN4 (netrin 4) genes, a kit, and a method thereof. The composition for diagnosing metastatic characteristics or estimating the metastasis riskness of ovarian cancer contains an agent for measuring the CpG methylation status of the NTN4 (netrin 4) genes. The agent contains: a compound deforming a non-methylated cytosine base or a methylation sensitive restriction enzyme; a primer specific to a methylated sequence of a CpG domain of the NTN4 genes; and a primer specific to a non-methylated sequence.

    Abstract translation: 本发明涉及通过检测NTN4（netrin4）基因的CpG甲基化状态，试剂盒及其方法来诊断转移特征或估计卵巢癌转移风险的组合物。 用于诊断转移特征或估计卵巢癌转移风险的组合物含有测定NTN4（netrin4）基因CpG甲基化状态的试剂。 该试剂含有：使非甲基化胞嘧啶碱基或甲基化敏感性限制酶变形的化合物; 特异于NTN4基因的CpG结构域的甲基化序列的引物; 以及对非甲基化序列特异性的引物。

    ＨＭＯＸ１ 유전자의 메틸화 변화를 이용한 알츠하이머 질환의 진단용 조성물 및 이를 이용한 알츠하이머 질환의 진단방법
    35.
    发明授权
    ＨＭＯＸ１ 유전자의 메틸화 변화를 이용한 알츠하이머 질환의 진단용 조성물 및 이를 이용한 알츠하이머 질환의 진단방법 有权
    使用HMOX1基因的甲基化状态诊断阿尔茨海默病的组合物和使用其来诊断阿尔茨海默病的方法

    公开(公告)号：KR101302173B1

    公开(公告)日：2013-08-30

    申请号：KR1020120141957

    申请日：2012-12-07

    Applicant: 이화여자대학교 산학협력단

    Inventor： 안정혁 ,  성혜윤

    IPC: C12Q1/68 ,  C12N15/11

    CPC classification number: C12Q1/6883 ,  C12Q2600/154 ,  C12Q1/683 ,  C12Q1/6865

    Abstract: PURPOSE: A composition for diagnosing Alzheimer's disease is provided to diagnose Alzheimer's disease by identifying the methylation of a heme oxygenase 1 (HMOX1) gene promoter using a biomarker. CONSTITUTION: A composition for diagnosing Alzheimer's disease contains a formulation which measures the methylation level of a HMOX1 gene promoter. A method for providing information for diagnosing Alzheimer's disease comprises the steps of: measuring the methylation level of the HMOX1 gene promoter from a biological sample of a patient who is suspected to have Alzheimer's disease; and comparing the measured methylation level with the methylation level of a control group sample.

    Abstract translation: 目的：提供一种用于诊断阿尔茨海默氏病的组合物，通过使用生物标志物鉴定血红素加氧酶1（HMOX1）基因启动子的甲基化来诊断阿尔茨海默病。 构成：用于诊断阿尔茨海默病的组合物含有测量HMOX1基因启动子的甲基化水平的制剂。 一种提供用于诊断阿尔茨海默病的信息的方法，包括以下步骤：从疑似患有阿尔茨海默病的患者的生物样品中测量HMOX1基因启动子的甲基化水平; 并将测得的甲基化水平与对照组样品的甲基化水平进行比较。

Patent Agency Ranking